4P-Pharma Welcomes Marina Vasiliou, Christian Bechon, and Alain Sainsot as Independent Members of Its Board

10.9.2024 07:30:00 CEST | Business Wire | Press Release

4P-Pharma, a clinical-stage startup based in Lille that develops disease-modifying therapies for untreated serious diseases, is delighted to welcome Marina Vasiliou, Christian Bechon, and Alain Sainsot as independent and non-executive members to its Board of Directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240909483462/en/

4P-Pharma welcomes Marina Vasiliou, Christian Bechon and Alain Sainsot as independent members of its board (Photo: Business Wire)

These novel additions will strengthen 4P-Pharma's goal to become a commercial-stage, fully integrated biopharma company covering the whole value chain from discovery to commercialization.

Revital Rattenbach, CEO of 4P-Pharma, says: "We proudly welcome three exceptional leaders to our Board of Directors. Each new member brings substantial expertise and proven leadership abilities, which are crucial to 4P-Pharma during this period of significant company growth."

Concerning the new members:

Marina Vasiliou, Biogen France President and Managing Director

Marina Vasiliou has been serving as the President and Managing Director of Biogen France since 2021. Biogen is a pioneering international biotechnology company at the forefront of science and innovation, developing tomorrow's medicines in neurology, neuropsychiatry, immunology, and rare diseases. Marina Vasiliou's insights are essential in navigating regulatory requirements and market access strategies. She has experience managing commercial launches and reimbursement in different international settings, including the US, mainly in chronic and rare disease therapies.

"Contributing with my global commercial leadership expertise to supporting 4P-Pharma ambition fills me with great satisfaction. I fully believe in the company's mission to enhance patients' access to first-in-class therapies for untreated serious diseases. I trust the commitment and innovation of 4P-Pharma's CEO and executive team, and I am thrilled to work with them on a diverse Board of Directors," declared Marina Vasiliou.

Christian Bechon, Senior Partner chez Isalys Augmented Management

Christian Bechon is the former Chairman and CEO of LFB Group. Under his leadership, LFB Group has transformed from a French leader in plasma cell fractionation to an internationally recognized player with a global footprint.

"4P-Pharma is a promising French biotech company that prioritizes patients' needs. The company's main objective is to contribute to healthcare innovation in France and Europe while maintaining its independence. I am privileged to be a part of this entrepreneurial journey and provide valuable guidance to the leadership team to catalyze 4P-Pharma’s next wave of growth," said Christian Bechon.

Alain Sainsot, GTP Bioways founder and President

Alain Sainsot, Founder and President of GTP Bioways, has served as Senior Director of Group Operations and Logistics for leading pharmaceutical companies like Pierre Fabre. He is a serial industrial entrepreneur who created two fast-growing CDMOs, Amatsi-group (acquired) and GTP-Bioways. He brings extensive experience in the industrial anchor of drug development to 4P-Pharma.

"It is an honor for me to join 4P-Pharma in their mission to develop innovative drugs for patients. I am confident in Revital Rattenbach's dedication and her leadership team's commitment to providing first-in-class treatments to patients. I look forward to joining forces and implementing the highest quality standards to industrialize 4P-Pharma's promising therapeutic pipeline further," stated Alain Sainsot.

Concerning the Board of Directors of 4P-Pharma

These new members reinforce the existing 4P-Pharma Board of Directors, which is composed of robust and well-known life science experts.

Their comprehensive industry knowledge and extensive network strengthen the company's credibility and strategic vision in the biotech and pharma sectors.

Jean Pierre Lehner,Chairman of the 4P-Pharma Board of Directors, concluded: "I am thrilled by Marina Vasiliou, Christian Bechon, and Alain Sainsot's enthusiasm for joining our Board. Their combined expertise will accelerate our mission and strengthen our ability to bring innovative therapies to those in need."

About 4P-Pharma

Founded in 2014, 4P-Pharma is a clinical-stage biotechnology company based in Lille dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Our goal is to bring first-class medicines to patients rapidly. 4P-Pharma leverages drug candidates with reduced development times, partly thanks to regulatory opportunities (emergency use or conditional market authorization) with strong intellectual property. The company is headquartered in Lille and Paris and has over 20 employees.

Website: https://www.4movingbiotech.com/
LinkedIn: https://fr.linkedin.com/company/4moving-biotech
X: https://twitter.com/4Moving_Biotech

The only version of the 4P-Pharma press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240909483462/en/

Contacts

Press Contact
Communication – media Relations
Emmanuel Dadjé - Communication Manager
Emmanuel.dadje@4P-Pharma.com
Tel : +33 6 30 06 12 13

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Selects MEVION S250-FIT ™ for Southern Italy’s First Proton Therapy Center17.5.2026 08:00:00 CEST | Press Release

Mevion Medical Systems, the global leader in compact proton therapy, today announced that it has been selected to deliver the MEVION S250-FIT Proton Therapy System™ to Istituto Nazionale Tumori IRCCS Fondazione G. Pascale in Naples. The award, made following a competitive European tender, will establish the first proton therapy center in Southern Italy, significantly expanding access to advanced radiation therapy for patients across the region and reducing the need for patients to travel long distances to northern Italy for care. Until now, proton therapy in Italy has only been available at centers located in Northern Italy, requiring patients from Southern Italy to travel significant distances for care. The Pascale project supports a broader strategy to establish Naples as a leading oncology hub and to improve healthcare equity across Italy. “The selection of the MEVION S250-FIT reflects our commitment to bringing advanced, accessible cancer care to patients in Southern Italy,” said D

TetraMem Announces 22nm Multi-Level RRAM Analog In-Memory Computing SoC Milestone16.5.2026 10:43:00 CEST | Press Release

TetraMem Inc., a Silicon Valley–based semiconductor company developing analog in-memory computing (IMC) solutions, today announced the successful tape-out, manufacturing, and initial silicon validation of its MLX200 platform, a 22nm multi-level RRAM-based analog IMC system-on-chip (SoC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260516556464/en/ Photograph of the MLX200 chip with a five-cent coin for size reference The achievement marks a significant step toward the commercialization of analog computing architectures based on emerging non-volatile memory technologies, addressing the growing challenges of data movement, power consumption, and thermal constraints in modern AI systems. As AI workloads continue to scale, system performance is increasingly constrained by the cost of moving data between memory and compute units. Analog in-memory computing offers a fundamentally different approach by performing computation dir

NTT DATA Announces Intent to Acquire WinWire to Scale Enterprise AI Adoption and Accelerate Industry Transformation with Microsoft15.5.2026 18:36:00 CEST | Press Release

NTT DATA, a global leader in AI, digital business and IT services, today announced it has signed a definitive agreement to acquire WinWire,an award-winning Microsoft partner specializing in Agentic AI, AI on Azure, data engineering and cloud-native development as foundational capabilities for enterprise AI. The acquisition strengthens NTT DATA’s position as a trusted partner to help organizations move beyond experimentation to operationalize AI at scale. The acquisition further advances NTT DATA’s enterprise AI strategy as demand accelerates for AI-driven, cloud-native transformation. By expanding capabilities across data platforms, agentic AI and modern applications, NTT DATA is sharpening its ability to deliver production-ready AI solutions aligned to industry needs, reinforcing its leadership as Microsoft’s Global System Integrator (GSI) Growth Champion Partner of the Year. Upon closing, WinWire will add more than 1,000 skilled Azure engineers and Microsoft specialists to NTT DATA,

STARTEEPO Invest Announces 5% Stake in Xerox Holdings Corporation15.5.2026 18:15:00 CEST | Press Release

STARTEEPO Invest (“STARTEEPO”), an alternative investment fund focused on public equity opportunities, today announced that it has acquired a significant ownership position in Xerox Holdings Corporation (“Xerox” or the “Company”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515594020/en/ As of the date of this release, STARTEEPO and its affiliates beneficially owns 6.6 million shares of Xerox (excluding options), representing approximately 5.05% of the Company’s outstanding common stock. STARTEEPO has filed a Schedule 13D with the U.S. Securities and Exchange Commission (the “SEC”) providing additional details regarding its investment. Investment Perspective STARTEEPO believes that Xerox represents an interesting investment opportunity supported by a combination of balance sheet initiatives, ongoing operational improvements, and its position within a changing and consolidating industry. In STARTEEPO’s view, the Company

NTT DATA Announces Intent to Acquire WinWire to Scale Enterprise AI Adoption and Accelerate Industry Transformation with Microsoft15.5.2026 16:00:00 CEST | Press Release

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom